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guidance, and synaptogenesis by activating the GTPase RAC1 and modulating actin cytoskeleton remodeling. Pathogenic variants in
TRIO are associated with neurodevelopmental diseases, including intellectual disability (ID) and autism spectrum disorders (ASD).
Here, we report the largest international cohort of 24 individuals with confirmed pathogenic missense or nonsense variants in TRIO.
The nonsense mutations are spread along the TRIO sequence, and affected individuals show variable neurodevelopmental phenotypes.
In contrast, missense variants cluster into two mutational hotspots in the TRIO sequence, one in the seventh spectrin repeat and one in
the RAC1-activating GEFD1. Although all individuals in this cohort present with developmental delay and a neuro-behavioral pheno-
type, individuals with a pathogenic variant in the seventh spectrin repeat have a more severe ID associated with macrocephaly than do
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Introduction
The Rho guanosine triphosphatases (GTPases) play an
essential role in many neurodevelopmental steps,
including neurogenesis, migration, and the formation of
synapses, by regulating actin cytoskeleton dynamics.1
They are activated by guanine nucleotide exchange fac-
tors (GEFs) that catalyze guanosine diphosphate (GDP)
dissociation and allow the binding of guanosine triphos-
phate (GTP). By facilitating this GDP-to-GTP exchange,
GEFs act as intermediaries between an external cue and
the activation of Rho GTPases.2 TRIO is a highly
conserved GEF that contains two GEF domains and
numerous accessory motifs, including spectrin repeats at
its N terminus.3 TRIO is a member of a small Rho-guanine
nucleotide exchange factor (RhoGEF) sub-family that
includes two functional GEF domains. The first GEF
domain (GEFD1) regulates RAC1 and RHOG activity,
and the second GEF domain (GEFD2) regulates RHOA ac-
tivity.4,5 It is recognized that through RAC1 activation
and actin cytoskeleton remodeling, TRIO acts as a major
regulator of cytokinesis, cell migration, axon outgrowth,
axon guidance, and dendritic arborization and plays a
role in synaptogenesis by modulating excitatory synaptic
transmission.6–10
The importance of TRIO in development is demon-
strated inmurinemodels. TRIO knockout inmice is embry-
onically lethal, and embryos show abnormalities in
skeletal muscle and neural-tissue development.11 Mice in
which TRIO has been specifically deleted in the nervous
system die perinatally, and the few mice that survive
display defects in the migration of cerebellar granule
cells.12 Heterozygous or homozygous deletion of TRIO in
the hippocampus and in the cortex during early embryo-
genesis results in progressive defects in learning ability, so-
ciability, and motor coordination of these mice.13–15
Whole-exome sequencing studies have identified several
deleterious de novo mutations in TRIO in different cohorts
of individuals with neurodevelopmental disorders,
including intellectual disability (ID) and/or autism spec-
trum disorders (ASD).16–19 In addition, TRIO has been re-
ported as intolerant to functional genetic variation.20
The reported clinical phenotypes of affected individuals
with TRIOmutations include intellectual disability, behav-
ioral difficulties such as hyperactivity or aggression, autism
or autistic behavioral tendencies, skeletal hand anomalies,
and microcephaly. Pathogenic variants include missense
mutations and nonsense mutations, the latter of which
generates premature stop codons leading to truncated pro-
teins or haploinsufficiency. Missense mutations in TRIO
often target TRIO’s RAC1-activating domain, GEFD1. For
the GEFD1 mutants on which there have been functional
studies, the majority show a reduction in TRIO-mediated
activation of RAC1,17–19 but some also affect glutamatergic
synaptic transmission, reinforcing the hypothesis that
TRIO mutations are causative of these neurodevelopmen-
tal disorders.18The AmeriIn addition to this cluster of missense mutations target-
ing the GEFD1, we have previously described an individual
harboring a missense mutation in one of the spectrin
motifs.17 In comparison to the severe microcephaly seen
in individuals with mutations in the GEFD1, this person
had a head circumference in the 75th centile.17 This sug-
gests that the position of the mutation in the TRIO
sequence could differentially impact TRIO’s neuronal func-
tion and cause phenotypic heterogeneity.
Here, we report on an important set of individuals
harboring pathogenic TRIO (MIM: 601893) variants, in-
cluding nonsense and missense mutations. The nonsense
mutations are spread along the TRIO sequence, and indi-
viduals show variable neurodevelopmental phenotypes.
With regard to the missense mutations, we have identified
the seventh spectrin domain of TRIO as a second muta-
tional hotspot and describe how this gives rise to a distinct
phenotype of severe neurodevelopmental delay, macroce-
phaly, and TRIO-mediated RAC1 hyperactivity. This is in
contrast to the GEFD1 hotspot, which is mostly associated
with milder ID, microcephaly, and reduced TRIO activity.
In addition, expression of TRIO variants in the vertebrate
model X. tropicalis induces defects that are concordant
with the human phenotype, showing that TRIOmutations
are causative of these neuordevelopmental disorders. Alto-
gether, we propose that, depending on the domain tar-
geted, mutations affect TRIO’s function in opposite ways
and give rise to two seemingly diverse clinical syndromes:
severe developmental delay and macrocephaly (spectrin
variants) versus a milder developmental phenotype and
microcephaly (GEFD1 variants). These findings highlight
the importance of tight control of TRIO-RAC1 signaling
during neuronal development.Material and Methods
Identification of Pathogenic TRIO Variants
Pathogenic variants in TRIO were identified by whole-exome
sequencing performed on whole blood DNA as part of the Deci-
phering Developmental Disorders (DDD) Research Study,21 as
part of a research study at TGenWIRB Protocol #20120789, Geno-
mics England 100,000 Genomes Project (see The National
Genomics Research and Healthcare Knowledgebase v5 in Web Re-
sources), or through diagnostic clinical practice. The DDD study
collated more than 12,000 affected individuals with undiagnosed
neurodevelopmental disorders. Variants were reported according
to standardized nomenclature defined by the reference human
genome GRCh37 (hg19) and TRIO transcript GenBank:
NM_007118. The minor-allele frequency of each variant was
determined from genomic sequencing data derived from the gno-
mAD, and the effect of each genomic variant on protein function
was predicted with the Ensembl Variant Effect Predictor.22 None of
the missense variants are listed in the gnomAD.
Aberrant Splicing Analysis
Blood was collected from individual 19, and RNA was extracted
from the blood sample with the PAXgene Blood RNA Kit
(PreAnalytiX). cDNA synthesis was performed with the Highcan Journal of Human Genetics 106, 338–355, March 5, 2020 339
Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific). The TRIO variant (c. 48602A>G) is located on the in-
tronic splice acceptor site of exon 33 (GenBank: NM_007118.4),
and the primer pairs (pair 1 [forward] 50-AGTGGGAGAAGCA
AGTACCT-30/[reverse] 50-CTGTCGTCGGAGTCCTTCTG-30 and
pair 2 [forward] 50-AGAACGGCATCTCTTCCTTTT-0/[reverse]
50-CACTGTCGTCGGAGTCCTT-30) (Integrated DNA Technolo-
gies) were designed on the flanking exon 30 and exon 35. PCR
was performed with the GoTaq G2 Polymerase PCR system
(Promega). The amplicons were visualized under ChemiDoc
XRSþ (Bio-Rad). Amplicons for further analysis were cloned into
plasmids via a TA cloning kit with the pCR 2.1 vector (Thermo
Fisher Scientific). Plasmids carrying inserts were sequenced by
Sanger sequencing (Source Bioscience). Bioinformatic predictions
for aberrant splicing were performed with Human Splicing Finder
(version 3.1),23 MaxEntScan,24 and Splice Site Finder by Neural
Network (SSFNN).25Patient Consent
Patient consent for participation and phenotyping was obtained
through the referring clinical team. Referring clinicians were re-
quested to complete a comprehensive phenotyping questionnaire
that was based upon our current understanding of the phenotypic
associations of TRIO. This included sections related to neurodeve-
lopmental screening; dysmorphology; and gastrointestinal, skel-
etal, and cardiac phenotypic features. Consent and collection of
information conformed to the recognized standards of the Decla-
ration of Helsinki.Quantitative Facial Phenotyping
Clinical photographs of individuals’ faces were analyzed accord-
ing to the hybrid model reported previously.26,27 This model
combines two algorithms (OpenFace28 and Clinical Face Pheno-
type Space29) used for facial recognition to create a 468-dimen-
sional vector of the facial features of a given individual. These
vectors are used for calculating the clustering impact factor
(CIF) of a patient group. This is a measurement of how a
group of individuals cluster within a group of controls; these
controls are age-, ethnicity-, and gender-matched individuals
with intellectual disability (see van der Donk et al.26 for further
technical details). The Mann-Whitney U test is utilized for
determining whether the CIF is significantly higher than ex-
pected on the basis of random chance. This was done for all in-
dividuals, including the subset of individuals with mutations in
either of the domains (GEFD1 and spectrin), so that the facial fea-
tures of individuals with mutations in these different domains
could be assessed for differences. A p value smaller than 0.0125
(0.05/4) was considered significant, after correcting for multiple
testing.Molecular Modeling of TRIO Domains
We modeled the structure of the seventh spectrin repeat of TRIO
on the basis of the crystal structures of human beta2-
spectrin (PDB ID 3EDV30) by using a sequence alignment ob-
tained from the generalized sequence profile.31 The model was
constructed by the SWISS-MODEL server.32 The structure of
the DH1 domain of TRIO in complex with the small GTPase
substrate RAC1 was modeled with the crystal structures of
DH1 (PDB: 1NTY) and the complex with substrate
(PDB: 1KZ7). Data for the protein structures were generated
with PyMOL.33340 The American Journal of Human Genetics 106, 338–355, MarchPlasmids and DNA Constructs
The pbio-EGFP-TRIO and pbio-EGFP-TRIO GEF-dead constructs
have been described previously.7,34 All the missense and nonsense
mutants were generated with the QuikChange Site-directed muta-
genesis kit (Agilent Technologies) according to the manufacturer’s
instructions; appropriate primers were used. Primer sequences are
available upon request. All constructs were verified by sequencing.
pLXSN-myc-Rac1T17N has been described previously.35 The pRK5-
Myc-PAK1 construct was a kind gift from Nathalie Lamarche-Vane
(McGill Cancer Research Center, Montreal, Canada).
Cell Culture and Transfection
N1E-115 and HEK293T cells were cultured at 37C in Dulbecco’s
modified Eagle’s medium (DMEM; Eurobio) supplemented with
10% fetal bovine serum, 2 mM L-glutamine (Invitrogen), and
penicillin and streptomycin (Invitrogen) under humidified condi-
tions with 5% CO2.
For the neurite outgrowth assays, N1E-115 cells were seeded in
35 mm dishes containing 12 mm glass coverslips coated with
laminin (25 mg/mL; Sigma Aldrich). HEK293T cells were seeded
in 100 mm dishes. Cells were transfected with TRIO constructs
as indicated with the JetPEI reagent (Polyplus) at 1:5 (for N1E-
115 cells) and 1:3 (for HEK293T cells) ratios, as described previ-
ously.36
RAC1N17 Binding Assay
HEK293T cells were co-transfected with the indicated biotinylated
pbioGFP-TRIO variants and a pLXSN-Myc-RAC1N17 plasmid. 48 h
after transfection, cells were lysed in lysis buffer [50 mM Tris HCl
(pH 7.5), 1 mM EGTA, 1 mM EDTA, 0.1% (w/v) Triton X-100,
1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM
sodium pyrophosphate, 10% sucrose, 1 mM dithiothreitol,
0.5 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride
(AEBSF)]. TRIO was pulled down with Streptavidin Dynabeads (In-
vitrogen), and the co-precipitating RAC1N17 was detected via
immunoblotting with a RAC1 antibody (BD Biosciences,
#610651). Total cell lysates were analyzed with the relevant anti-
RAC1 and anti-GFP antibody (Torrey Pines Biolabs, #TP401).
Neurite Outgrowth and Lamellipodia Analysis
More than 200 transfected N1E-115 cells were analyzed for each
condition. A neurite was defined as a process thatmeasured at least
twice the length of the cell body. Lamellipodia were defined as
sheet-like rhodamine-phalloidin-positive protrusions, occurring
along or at the tip of the neurite. The proportion of transfected
cells harboring a neurite or a lamellipodium was determined
manually in an experimenter-blinded procedure. Values obtained
from no less than five independent experiments were presented as
n-fold change over wild-type (WT) TRIO, which was arbitrarily set
to 1. A Student’s unpaired t test was used for statistical analysis.
Immunoblot Analysis of Phospho-PAK Amounts
HEK293T cells were co-transfected with the indicated pbioGFP-
TRIO variants and a pRK5-PAK1 plasmid. 48 h after transfection,
cells were lysed in lysis buffer, and amounts of phosphorylated
PAK1 were monitored by immunoblot analysis with a phospho-
Ser144 PAK antibody (# 2606S, Cell Signaling) and a monoclonal
PAK1 antibody (sc-166887). Total TRIO expression was detected
with a GFP antibody (Torrey Pines Biolabs, #TP401). Immunoblot
detections and band-intensity quantifications were made with the
Odyssey system from Li-COR Biosciences.5, 2020
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Figure 1. Pathogenic TRIO Variants Found in Individuals with Neurodevelopmental Disorders
(A) Schematic representation of TRIO domains with annotated missense and nonsense mutations identified in affected individuals. Pa-
tient groups 1 and 2 are highlighted in green and orange, respectively. Missense mutation p.Pro1461Leu is in blue so that it is differen-
tiated from the other GEFD1mutants (see text for details). Nonsense variants are written in black. The numbers in brackets correspond to
the OFC of each affected individual (þ/SD).
(B) Clinical photographs of individuals carrying an alteration in the seventh spectrin repeat domain of TRIO (group 1). Individuals 2
and 3 have the p.Arg1078Trp variant, individuals 7 and 8 have the p.Arg1078Gln variant, and individual 9 has the p.Asn1080Ile
variant.17
(legend continued on next page)
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Animal Maintenance and Embryo Generation at the
European Xenopus Resource Center
All work presented was conducted in accordance with the con-
ditions set out by the UK’s Home Office legislation under PPL
70/6450 (Professor Matthew Guille: European Xenopus Resource
Centre) and approved by the University of Portsmouth’s Animal
Welfare Ethical Review Body. Outbred Nigerian Xenopus tropica-
lis were maintained in recirculating systems with 15% daily wa-
ter changes and temperatures between 25C–27C and main-
tained on a 13–11 h light-dark cycle. Adult X. tropicalis were
fed thrice daily five days per week with Skretting Horizon 23 pel-
lets. Sexually mature female X. tropicalis were primed the eve-
ning before collection with 10 IU hCG and a boosting dose of
100 IU hCG the following morning. Egg clutches were obtained
via gentle abdominal massage and fertilized with cryopreserved
sperm.
Frozen X. tropicalis spermatozoa were generated from adult
male X. tropicalis exhibiting enhanced nuptial pads. Sperm cryo-
preservation followed an adapted protocol initially developed by
Sargent and Mohun37 and modified by Mansour38 with further
amendments implemented within the European Xenopus
Resource Centre.39 Cryopreserved spermatozoa were rapidly
thawed in a 37C water bath. Two volumes of 0.1 3Marc’s Modi-
fied Ringer’s Solution (MMR: 0.01 M NaCl, 0.2 mM KCl, 0.1 mM
MgSO4, 0.2 mM CaCl2, and 0.5 mM HEPES [pH 7.4]) was then
added to the thawed spermatozoa, and the solution was applied
directly to eggs manually spread to a monolayer. Embryos were
maintained in 0.05 3 MMR (containing penicillin [5 U/mL]
and streptomycin [5 mg/mL]) with 50% daily media changes at
25.5C in 145 mm tissue-culture Petri dishes at a density of 50
embryos (or fewer) per dish.Use of CRISPR-Cas for Generation of Knock-Out Animals
Xenopus tropicalis target regions of interest were identified through
Xenbase, and four single-stranded oligonucleotides (Table S2)
directed at multiple loci within TRIO were designed with
CRISPRscan. Subsequently, single-guide RNAs were generated
according to the PCR-based method described by Nakayama and
colleagues.40 X. tropicalis embryos were co-injected at the one-
cell-stage with 500 pg single-guide RNA and 2.5 mg Cas9 (spy
Cas9 NLS, NEB) with the microinjection apparatus and procedure
described in Guille.41 Genomic DNA was extracted from individ-
ual embryos with QIAGEN’s DNeasy Blood and Tissue Kit. Primers
(Table S2), designed in Primer3, were used for amplification of the
target regions of interest for analysis. T7 Endonuclease I (NEB),
which recognizes and cleaves mismatched DNA, was used for
identification of the most effective single-guide RNA for each
site.42 Sanger sequencing of PCR-amplified regions confirmed
these indels in mutant embryos. Tadpoles were imaged with a
ZEISS Axio Zoom.V16 Stereomicroscope. All analyses were imple-
mented with packages in R version 3.5.1. Differences in head
diameter between treatments were analyzed via a one-way analysis
of variance (ANOVA). A Tukey honestly significant difference
(HSD) post-hoc test was used.(C) Clinical photographs of individuals carrying an alteration in the G
10–16 harbor the following variants: (10) p.Glu1299Lys, (11 and 12) p
p.Pro1461Leu.
(D) Clinical photographs of individuals carrying nonsense mutations
are related;17 patient 17a is the daughter of individual 17b. Individu
nonsense variants p.Gln768*, p.Arg1620Serfs*10, and p.Val2351Cys
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Cohort of Individuals with Pathogenic Variants in TRIO
Here, we present the largest phenotypic cohort of individ-
uals who had confirmed pathogenic variants in TRIO and
who presented with neurodevelopmental delay. Through
a combination of DDD and internationally ascertained
participants, we recruited 24 individuals from 22 families.
Pathogenic TRIO variants were de novo in 21 families and
inherited in one family. The mechanism of inheritance
was not described in three families. Different variant types
were observed: 16 missense variants (nine within the
N-terminal spectrin repeat domain and seven within the
GEFD1), seven nonsense (protein-truncating) variants,
and one consensus splice-site variant (Figure 1A, Table 1).
Missense mutations were clustered into two main
groups: the seventh spectrin repeat domain of TRIO
(group 1) and the GEFD1 (group 2) (Figure 1 A). Individuals
1 to 9 harbor missense mutations in the seventh spectrin
repeat at the N terminus of TRIO (Figure 1A, Tables 1 and
S1). Interestingly, these variants cluster within only three
amino acids (Thr 1075, Arg 1078, and Asn 1080). Within
group 1, we demonstrate a consistent phenotype of severe
intellectual disability and macrocephaly (Figure 1B, Tables
1 and S1). Individuals 10 to 16 carry missense mutations in
residues within the RAC1-activating GEFD1; such residues
include two amino acids (Arg 1428 and Pro 1461) mutated
in several unrelated patients (Figure 1A). These individuals,
except individuals 15 and 16, define patient group 2 and
present with milder ID and microcephaly. Individuals 15
and 16 (harboring the p.Pro1461Leu mutation) were
excluded from group 2 in our analysis because they pre-
sented no microcephaly (Figure 1C, Tables 1 and S1).
A third group of persons, individuals 17 to 22, carry
nonsense mutations throughout the TRIO sequence but
have no specific mutational cluster and show a more
variable neurodevelopmental phenotype (Tables 1 and
S1, Figures 1A and 1D). These nonsense mutations
presumably lead to the formation of a truncated protein,
featuring only parts of the functional domains of TRIO.
Individuals 17a–17c carry an inherited nonsense GEFD1
mutation, p.Gln1489Argfs*12 (reported previously as
p.Gln1489Argfs*11),17 generating a truncated and thus
non-functional GEFD1. Interestingly, they present with a
phenotype similar to that of group 2 patients. Alterna-
tively, the frameshift mutants, and especially mutant
p.Gln768* at the N terminus of TRIO, could be subject to
nonsense-mediated decay of the truncated transcript;
such decay could result in negligible protein production
and haploinsufficiency. Of interest, individual 19 carriesEFD1 of TRIO (group 2 and the p.Pro1461Leu variant). Individuals
.Arg1428Gln, (13) p.Pro1461Thr,17 (14) p.His1469Arg, (15 and 16)
: individuals 17a–17c all carry the p.Gln1489Argfs*12 variant and
als 17b and 17c are brothers. Individuals 18, 19, and 21 carry the
fs*62, respectively.
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Table 1. Individual Clinical Phenotype
Group 1 Individuals Group 2 Individuals
Patient 1 2 3 4 5 6 7 8 9 10 11 12
TRIO variant
Coding change c.3224C>T c.3232C>T c.3232C>T c.3232C>T c.3232C>T c.3232C>G c.3233G>A c.3233G>A c.3239A>T c.3895G>A c.4283G>A c.4283G>A
Protein change p.Thr1075Ile p.Arg1078Trp p.Arg1078Trp p.Arg1078Trp p.Arg1078Trp p.Arg1078Gly p.Arg1078Gln p.Arg1078Gln p.Asn1080Ile p.Glu1299Lys p.Arg1428Gln p.Arg1428Gln
Domain spectrin spectrin spectrin spectrin spectrin spectrin spectrin spectrin spectrin GEFD1 GEFD1 GEFD1
Inheritance NR de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo
Sex M M M M M M F F F M F F
Age last
assessment
15 years 12 years 3 years 4 years 7 years 6 years 19 years 40 years 9 years 20 months 16 years 8 years
First smile NR NR <36 weeks 52 weeks NR normal NR 24 weeks NR 12 weeks 8 weeks 6 weeks
Sitting
unsupported
12 months NR NA 36 months 36 months 7 months 10.5 months 9 months 11 months 9 months 10 months 8 months
Walking
unaided
30 months 84 months NA, crawling NA NA 24 months 24 months 36 months 48–60 months NA 22 months 12 months
First words 66 months NR NA NA 36 months NA 48–60 months 52 months NR 24 months NR NR
Learning
Difficulties
yes; moderate yes; severe yes; severe yes; severe yes; severe yes; severe yes; moderate yes; severe yes; severe yes; moderate missing level
in charts
yes; moderate
Language delay:
Expression
yes; dysarthria,
short sentences
yes; 50 words
at 7 years
yes; babble
only
yes; babble
only
yes; <10 words yes; severe,
sounds only
yes; impaired
articulation
yes; short
sentences only
yes; non-verbal,
uses Makaton
yes; only a few
two- syllable
words
yes; very
talkative
yes; talkative
Language delay:
Comprehension
yes yes yes yes yes yes;
comprehension
better
yes yes yes yes yes; unable
to read or write
yes
OFC þ0.7 SD þ2.9 SD þ2.2 SD þ2.7 SD þ2.8 SD þ3 SD þ2.4 SD þ4.7 SD þ1.8 SD 3.8 SD 5.9 SD ‘‘microcephaly’’
Other genetic
variants
NR 14q21.1
microdeletion
no no no NR no NR no no no maternally
inherited 4p
microdeletion
Reference
(patient)
this study this study this study this study this study this study this study this study 17 this study 17 this study
Variant
described in
- - - - - - - - 17 - 17, 18 17, 18
(Continued on next page)
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Table 1. Continued
Group 2 Individuals Truncation Individuals
Patient 13 14 15 16 17a (proband) 17b (father) 17c (uncle) 18 19 20 21 22
TRIO Variant
Coding change c.4381C>A c.4406A>G c.4382C>T c.4382C>T c.4466delA c.4466delA c.4466delA c.2302C>T c.48602A>G c.6092dup c.7050del c.7461del
Protein change p.Pro1461Thr p.His1469Arg p.Pro1461Leu p.Pro1461Leu p.Gln1489Argfs*
12
p.Gln1489Argfs*
12
p.Gln1489Argfs*
12
p.Gln768* p.Arg1620Serfs*
10
p.Leu2031Phefs*9 p.Val2351Cysfs*
62
p.Phe2473Serfs*
54
Domain GEFD1 GEFD1 GEFD1 GEFD1 truncating truncating truncating truncating truncating truncating truncating truncating
Inheritance de novo de novo de novo de novo inherited inherited inherited NR de novo de novo de novo NR
Sex F M F F F M M F F M M M
Age last
assessment
8 years 14 years 19 years 11 years 17 months 36 years 10 years 14 years 8 years 16 years 9 years 21 months
First smile 36 weeks NR 8 weeks 28 weeks NR NR NR NR NR 6 weeks >8 weeks 21 months
Sitting
unsupported
11 months 9 months 11 months 13 months 9 months NR NR NR 8 months 6 months NR NA
Walking
unaided
30–36 months 17 months 21 months 24 months 17 months NR NR 14 months 12 months 12 months >24 months NA
First words 48–60 months 60 months NR 24–36 months 17 months NR NR 24 months 10 months Delayed >18 months NA
Learning
difficulties
yes; global yes; mild yes; mild yes; moderate yes; mild yes; mild yes; mild yes yes; mild yes; severe yes; moderate yes; severe
Language
delay:
expression
yes yes; first
sentences
at 9 years
yes yes; literal
speech
yes NR NR yes yes yes; short
sentences
yes yes; no
language
development
Language
delay:
comprehension
yes no yes yes yes NR NR yes yes no yes yes
OFC 3.8 SD 4 SD þ1.5 SD 0.3 SD 3.3 SD 2.1 SD 3.9 SD 3.5 SD 4.4 SD 1.4 SD þ1.4 SD 4.6 SD
Other genetic
variants
- - no bi-allelic FAT4
variants
regarded
as VUS
no 15q11.2
microdeletion
and maternal
DM
15q11.2
microdeletion
no no no 5p15.31 VUS
paternally
inherited, father
phenotypically
normal
no
Reference
(patient)
17 this study this study this study 17 17 17 this study this study this study this study this study
Variant
described in
17, 18 - 18 18 - - - - - - - -
Description of the clinical phenotype observed among TRIO mutation carriers, grouped on the basis of variant location or protein effect: spectrin repeat (group 1), GEFD1 (group 2 and p.Pro1461Leu individuals 15 and 16)
and protein truncating. Abbreviations are as follows: M, male; F, Female; NR, not recorded; SD, standard deviation; OFC, occipitofrontal circumference; GORD, gastro-esophageal reflux disease; NG, nasogastric; and NA, not
achieved.
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Figure 2. Individuals Harboring Variants
in Either GEFD1 or Spectrin Domains
Show Distinct Neurodevelopmental Phe-
notypes
(A) Percentage of affected individuals with
different levels of learning difficulties in
either spectrin domain (group 1) or
GEFD1 (group 2) mutation cases. 75% of
group 2 individuals have mild-moderate
learning difficulties. 78% of group 1 indi-
viduals have severe learning difficulties.
(B) Early developmental milestones
(sitting unsupported, walking, and first
words) are delayed in both group 1 and
group 2 individuals, but group 1 individ-
uals are affected more severely. For
statistical analysis, refer to Table S3.
Walking: *p ¼ 0.035.
(C) Height and weight standard deviations
frommean in either group 1 or group 2 in-
dividuals. The median height for group 1
individuals with spectrin mutations was
1.69 SD, and for group 2 individuals
with GEFD1 mutations it was 1.34 SD.
33% of the individuals in group 1 and
14% of individuals in group 2 had a height
SD of greater than 2 SD, which is often
considered as short stature. Weight SD
was also reduced in both groups.
(D) Microcephaly was seen in 100% of
group 2 individuals, who had a mean
OFC of 3.82 SD (median OFC of 3.8
SD). Individuals within group 1 present
with macrocephaly. 78% had an OFC
greater than 2 SD from the mean; mean
OFC was þ2.6 SD, median OFC was þ
2.7 SD, and OFC range was between þ0.7
SD and þ4.7 SD. **p < 0.001 (Table S3)
(E) A neurobehavioral phenotype was
observed in 19 out of the 24 (79%) individ-
uals described in this study.
(F) Recurrent behavioral features include
stereotypies (6/24 patients), poor atten-
tion (14/24 individuals), obsessive-
compulsive traits (9/24 individuals), and
aggression (8/24 individuals). In total,
2/24 were identified as social or friendly.
(G and H) Quantitative facial phenotyp-
ing. t-distributed stochastic neighbor
embedding (t-SNE) plot of the vectors of individuals with alterations in GEFD1 and the seventh spectrin domain and the matched con-
trols with intellectual disability. The statistically significant clustering of individuals with mutations in the spectrin domain indicates a
recognizable facial phenotype.a splice variant, c.48602A>G. We confirmed pathoge-
nicity by validating the aberrant splicing by PCR and
found an extra amplicon in the PCR product of variant
c.48602A>G (Figure S1). Sanger sequencing results
show that the mutation caused disruption to the
splice acceptor site and activation of a new splice
acceptor site that is 51 base pairs upstream of exon 33;
the result was an abnormal intron inclusion transcript
(p.Arg1620Serfs*10).
Distinct Neurodevelopmental Phenotypes for
Individuals with Either Spectrin or GEFD1 Mutations
Affected individuals of the cohort were born at term with
no described antenatal or perinatal complications. All indi-The Amerividuals presented with neurodevelopmental delay, but
strikingly, the level of intellectual disability was more se-
vere among individuals with a pathogenic variant within
the spectrin repeat domain (group 1) than in individuals
with a variant in GEFD1 (group 2). Indeed, for group 1,
the most frequently observed level of intellectual disability
was moderate to severe (22% moderate and 78% severe),
whereas individuals within group 2 presented with mild
to moderate intellectual disability (50% mild and 25%
moderate) (Figure 2A).
Early developmental milestones, including sitting
without support, walking, and first words, were delayed
in both patient groups, but again, individuals with spectrin
mutations were affected more severely (Figure 2B). Incan Journal of Human Genetics 106, 338–355, March 5, 2020 345
addition, within group 1 there was a greater incidence of
individuals’ being unable to attain these developmental
milestones. For instance, individual 3 (3 years old) was un-
able to sit unsupported, walk, or talk; individual 4 (4 years
old) was unable to walk or talk; and individual 6 (6 years
old) was unable to talk (Tables 1 and S1).
Height and weight were reduced in individuals with
both spectrin and GEFD1 mutations. The median height
for individuals within group 1 was 1.69 SD, while for in-
dividuals in group 2 it was 1.34 SD (Figure 2C). In addi-
tion, 33% of the group 1 individuals and 14% of group 2
individuals had a height SD that was greater than 2 SD,
which is often considered as indicating short stature. Inter-
estingly, weight SD was also reduced to a greater extent in
individuals with spectrin variants; there was a mean
weight SD of 2.36 in group 1 individuals and a mean
weight SD of 2 in group 2 individuals (Figure 2C).
Most strikingly, we noticed a remarkable difference in
the occipitofrontal head circumference between individ-
uals with spectrin mutations and those with GEFD1 vari-
ants (Figure 2D). Microcephaly, which is defined by a
head circumference two SD below the mean, was seen in
100% of group 2 patients, with a mean occipitofrontal
circumference (OFC) of 3.82 SD (median OFC of 3.8
SD). In contrast, individuals in group 1 presented with
macrocephaly. In the spectrin cohort, 78% had an OFC
greater than two SD from the mean; mean OFC was þ2.6
SD, median OFC was þ 2.7 SD, and the OFC range was be-
tween þ0.7 SD and þ4.7 SD (Figure 2D).
A neurobehavioral phenotype was observed in 19/24
(79%) individuals with a TRIO variant, irrespective of the
mutated domain. Recurrent behavioral features seen across
all individuals included stereotypies (27%), poor attention
(70%), obsessive compulsive traits (45%), autistic traits
(31%), and aggression (36%) (Figures 2E and 2F). Three in-
dividuals (3/18, 17%) were reported to have pain insensi-
tivity or a higher tolerance of pain. There was a diagnosis
of epilepsy or evidence of seizure activity in five individ-
uals (24%). Interestingly, seizures were only reported in in-
dividuals with mutations in the spectrin domain (3/9) or
with truncating mutations (2/5) (Figure S2). Additional
symptoms were seen across all mutational domains,
including gastrointestinal problems, infantile feeding diffi-
culties, and constipation (Figure S2). Skeletal features,
including scoliosis, short tapering fingers, and delayed
dental eruption, were also noted in a number of affected
individuals. Interestingly, delayed dental eruption was
only seen in the individuals with GEFD1 or truncating mu-
tations, and one individual in the spectrin group was re-
ported to have opposing early primary dental eruption.
Structural cardiac and brain abnormalities were not
observed at a high frequency (Figure S2).
To determine whether individuals had a recognizable
facial phenotype, we used quantitative facial phenotyping
to analyze photos of the face by using the so-called hybrid
model as reported previously26 (Figures 2G and 2H). 13 in-
dividuals had photos, age, ethnicity, and gender available346 The American Journal of Human Genetics 106, 338–355, Marchand qualified for analysis. Four of these individuals had
mutations in the spectrin domain, and nine hadmutations
in the GEFD1. No significant difference in CIF was seen be-
tween controls and all individuals with TRIO mutations,
between controls and individuals with mutations in
GEFD1, or between individuals with GEFD1 mutations
and those with spectrin mutations. However, persons
with mutations in the spectrin domain did cluster signifi-
cantly when compared to the matched controls (Figures
2G and 2H). This indicates that these individuals have a
distinctive facial gestalt.
Taken together, these detailed phenotypic studies of in-
dividuals harboring a TRIO variant highlight two seem-
ingly distinct clinical syndromes. Individuals with spectrin
variants show a more severe developmental phenotype,
macrocephaly, and statistically significant clustering of
facial dysmorphism, whereas individuals with GEFD1 var-
iants have a less severe developmental phenotype and
microcephaly.
The Identified Mutations Target Crucial and Highly
Conserved Residues in TRIO
In order to gain insights into the mechanisms by which
the mutations identified in the two hotspots could affect
TRIO function, we set out to map the position of the mu-
tations on TRIO structure. For the cluster of variants in
the seventh spectrin repeat domain, we found that the
three residues Thr 1075, Arg 1078, and Asn 1080 are highly
conserved across evolution (Figure 3A). Of note, the argi-
nine residue at position 1078 is the most frequently
mutated: four unrelated individuals carry a tryptophan,
two carry a glutamine, and one carries a glycine residue
instead (Table 1). We modeled this seventh spectrin repeat
of TRIO on the crystal structures of human b2-spectrin and
found that it is composed of three a helices, the second of
which carries the cluster of residues 1075 to 1080
(Figure 3B). Axial views of these helices indicate how the
changed amino acids might perturb the global arrange-
ment of the helices (Figure 3C). In particular, being larger
than the original arginine residue and pointing toward
the inside of the domain structure, the mutated Trp 1078
causes an important steric hindrance.
For the GEFD1 cluster of variants, all the mutated amino
acids are conserved across evolution and lie within a heli-
ces that are also highly conserved among RhoGEFs. These
helices (helices a1, a5, and a6) are important for making
direct contact with the target GTPase and, hence, for acti-
vating the GTPase (Figures 3D and 3E).43 Given the poten-
tially crucial position of the mutated residues, we asked
whether these mutants would be impaired in the binding
of the GEFD1 to RAC1. We included the nonsense mutant
p.Gln1489Argfs*12 because it also targets a conserved res-
idue in the GEFD1 and thus leads to an incomplete and
potentially non-functional GEFD1. To address this ques-
tion, we performed pulldown assays in HEK293T cells
that were co-transfected with a TRIO cDNA carrying the
indicated mutations and a RAC1N17 construct, which is a5, 2020
Figure 3. Mapping of the Mutation Sites on the 3D Structure of the TRIO Spectrin 7 Repeat Domain and GEFD1
(A) Species conservation of the residues in TRIO’s seventh spectrin repeat, which is mutated in neurodevelopmental diseases. Identical
residues are labeled in red, and similar residues are in blue. The positions of the residues p.Thr1075, p.Arg1078, and p.Asn1080 are boxed
in black and indicated on top of the sequence, which encompasses amino acids 1053 to 1091, corresponding to the second a helix of the
spectrin repeat. Represented species are Homo sapiens (h), Mus musculus (m), Rattus norvegicus (r), Xenopus laevis (x), Danio rerio (z),
Drosophila melanogaster (d), and Caenorhabditis elegans (ce).
(B) Lateral view of the structural model of the seventh spectrin repeat of TRIO. The spectrin domain was modeled based on the crystal
structures of human beta2-spectrin (PDB ID 3EDV30) with our sequence alignment and SWISS-MODEL server.32 Parts of the structure
(legend continued on next page)
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dominant-negative form of RAC1 that mimics the GDP-
bound form of the GTPase and that binds the GEF with
higher affinity than WT RAC1 (Figure 3F). Bio-GFP TRIO
constructs were purified from the lysates with Streptavidin
beads, and the co-purifying RAC1N17 was revealed by
immunoblotting. As shown in Figure 3F, all the GEFD1
missense mutants and the nonsense p.Gln1489* mutant
were unable to bind RAC1N17, except that mutant
p.Pro1461Leu bound RAC1N17 to a similar extent as did
WT TRIO. These data confirm the crucial nature of the
GEFD1 residues found mutated in individuals with
microcephaly.Spectrin and GEFD1 TRIO Variants Cause Opposite
Modulation of RAC1 Activity
We next analyzed whether the mutations identified in in-
dividuals affected known functions of TRIO and could thus
contribute to the phenotypes observed in these persons.
We tested the effects of the variants on TRIO-mediated
activation of the RAC1 signaling pathway. Once in the
GTP-bound form, RAC1 is able to bind to the PAK1 kinase
and thereby to induce a conformational change that al-
lows for PAK1 auto-phosphorylation. We thus monitored,
as a readout for TRIO-mediated RAC1 activation, the levels
of PAK1 phosphorylation in HEK293T cells expressing the
different TRIO mutants (Figure 4A). All the missense
variants in the GEFD1 and the p.Gln1489* nonsense
variant led to decreased levels of phosphorylated PAK1
(on Ser 144), except for mutations p.Pro1461Thr and
p.Pro1461Leu, which respectively had no effect on or
slightly increased phospho-PAK1 levels. In contrast, and
surprisingly, all the variants in the seventh spectrin repeat
led to a strong increase in PAK1 phosphorylation, most
likely reflecting increased RAC1 activation (Figures 4A
and 4B). The truncation mutants p.Leu2031* and
p.Phe2473* had only a mild and non-significant effect,
respectively, on RAC1 activation.
By regulating the remodeling of the actin cytoskeleton,
TRIO plays a major role in neurite outgrowth and in the
formation of lamellipodia, which are sheet-like actin-rich
structures at the leading edge of the cell.44 To determine
whether the GEFD1 and spectrin variants affected thesethat were modeled with high and low confidence are in blue and c
affected individuals are indicated in red.
(C) Axial view of the cross section of the structure at the site of the m
(D) Sequence alignment of the RAC1-specific DH1 domain of TRIO (a
and similar residues are labeled in blue. The a helices are depicted sch
alterations p.Glu1299Lys, p.Arg1428Gln, p.Pro1461Leu, p.Pro1461T
mutation affects a highly conserved residue within helices a-1, a-5, a
sented species are Homo sapiens (h), Mus musculus (m), Rattus norvegic
and Caenorhabditis elegans (ce).
(E) Structure of the DH1 domain of TRIO (cyan) in complex with the
domain seen in affected individuals are indicated in red and can be
modeled with the crystal structures of DH1 (PDB: 1NTY) and the com
were generated with PyMol.33
(F) Most of the GEFD1 mutants are affected in their ability to bind to
assay of biotinylated TRIO variants. HEK293T cells were transfected
TRIO was pulled down with Streptavidin beads, and the co-precipita
348 The American Journal of Human Genetics 106, 338–355, Marchprocesses, we transfected N1E-115 neuroblastoma cells
with the different TRIO mutants and quantified neurite
outgrowth (Figures 4C and 4E) and lamellipodia formation
both along the shaft and at the tip of the neurite (Figures
4D and 4E). As shown in Figures 4C–4E, the spectrin vari-
ants all led to enhanced neurite outgrowth and lamellipo-
dia formation, reflecting almost perfectly the enhanced
RAC1 activation induced by these mutants (Figure 4B).
In contrast, the GEFD1 and the p.Gln1489* mutants
were impaired in forming neurites and lamellipodia,
although the p.Pro1461Thr and p.Pro1461Leu mutants
were notable exceptions. The truncation mutants
Leu2031* and Phe2473* had no effect on these processes.Truncation in the GEFD1 of TRIO CausesMicrocephaly in
X. tropicalis
Because technical limitations currently prevent us from
introducingmissensemutations inX. tropicalis, we assessed
the effect of TRIO truncation variants in this in vivomodel.
The target regions show>97% identity across the surround-
ing 200 residues between X. tropicalis and humans.
X. tropicalis embryos treated with CRISPR Cas produce tar-
geted indels at such high frequency that the resulting phe-
notypes can be analyzed in founder embryos.45–48 In this
study, CRISPR Cas targeting the different TRIO domains
was injected into fertilized eggs, and its effectiveness at pro-
ducing indels at the target sitewas assessed (Figure S3A).The
resulting tadpoles were raised to swimming tadpole stages,
at which point gross morphology, brain structure, and
head diameter were compared and examined. Two single-
guide RNAs were tested for each target locus, and each
pair produced the same phenotype (A.G. andM.G., unpub-
lished data), strongly suggesting that their effects were
target specific. Truncation of GEFD1 (hs: Glu 1489, xt: Glu
1450) had a clear effect on craniofacial development in
that it induced microcephaly in the affected tadpoles,
whereas minimal changes were observed in tadpoles with
truncation of GEFD2 (hs: Leu 2031, xt: Leu 1994) (Figures
5A and S3C).Measurement showed that therewasnodiffer-
ence in the head diameters of control individuals versus
those with the Leu 1994 truncation. The head diameters
of individuals with theGln 1450 truncationwere, however,yan, respectively. Mutations within the spectrin domain seen in
utations. Mutations are indicated in magenta.
nd KALIRIN) across evolution. Identical residues are labeled in red
ematically on top of the sequence alignment. The positions of the
hr, and p.His1469Arg are indicated in bold and boxed in red. Each
nd a-6, which make contact with the target GTPase RAC1. Repre-
us (r), Xenopus laevis (x), Danio rerio (z), Drosophila melanogaster (d),
small GTPase substrate RAC1 (green). Mutations within the DH1
seen to occur at the protein-substrate interface. The complex was
plex with substrate (PDB: 1KZ7). Figures of the protein structures
RAC1N17 (DN). Immunoblot analysis of a Streptavidin pulldown
with the indicated biotinylated GFP-TRIO variants and RAC1N17.
ting RAC1N17 was detected with a RAC1 antibody.
5, 2020
Figure 4. The Spectrin Mutants of TRIO Enhance RAC1 Signaling, Neurite Outgrowth, and Lamellipodia Formation in N1E-115 Cells,
Whereas the GEFD1 Mutants Are Mostly Impaired in These Processes
(A) Immunoblot analysis of HEK293T cell lysates transfected with the indicated GFP-TRIO variants and detected with an anti-GFP anti-
body (lower panel). PAK1 phosphorylation amounts are detected with a phospho-Ser144 PAK1 antibody (upper panel) and compared to
total PAK1 amounts detected with a PAK1 antibody (middle panel).
(legend continued on next page)
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Figure 5. Truncation in the TRIO GEFD1
Reduces Head Size in X. tropicalis
(A) X. tropicalis eggs from a single female
for each of two biological replicates (with
parents from different genetic back-
grounds) were fertilized with frozen sperm
and injected at the one-cell stage with
CRISPR-Cas targeting the genome as
shown. Representative micrographs for
each condition are shown (black and
white photos) (all tadpoles are shown in
Figure S3). Performing the GEFD1 and
GEFD2 frameshift in a tubb2B.GFP
X. tropicalis showed that forebrain defor-
mities had occurred in 6/8 GEFD1 trunca-
tion tadpoles, which was not the case for
GEFD2 frameshift. Representative micro-
graphs for each condition are shown (color
photos) (all tadpoles are shown in
Figure S4).
(B) Comparing the head diameter of the
tadpoles carrying truncations in the
GEFD1 (hs: Gln 1489* ¼ xt Gln 1450)
and GEFD2 (hs: Leu 2031* ¼ xt Leu 1994)
domains showed that GEFD1 truncations
caused microcephaly, whereas GEFD2
truncations had no effect. Quantification
is shown for eight individuals measured
(all tadpoles are shown in Figure S3).smaller than those of both the control group (ANOVA,
d.f ¼ 2, F ¼ 9.835, p ¼ 0.0027153) and individuals
with the Leu 1994 truncation (ANOVA, d.f ¼ 2, F ¼ 9.835,
p ¼ 0.0025286) (Figures 5B and S3B). This was despite the
fact that similar levels of indels were detected in the two
groups (Figure S3A). Gross structural abnormalities of the
brain were examined within the transgenic line NBT-GFP
[Xtr.Tg(tubb2b:GFP) Amaya], which labels differentiated
neurons. Embryos with an interruption in GEFD1 showed
clear deformation of the forebrain structures, whereas em-
bryos with truncation of GEFD2 (Leu 1994*) were unre-
markable (Figures 5A and S4).Discussion
Here, we report on an important set of individuals
harboring pathogenic TRIO variants resulting from a vari-
ety of nonsense or missense mutations.
We describe various nonsense mutations that are spread
along the TRIO sequence. We do not know whether these(B) Quantification of the ratio of phospho-PAK1 amounts over total P
activation of the RAC1 signaling cascade. Data are presented as the m
(C) Quantification of the neurite outgrowth induced byWTormutan
of cells harboring an extension of at least twice the length of the som
arbitrarily set to 1. Data are presented as the mean5 SEM of at leas
(D) Quantification of lamellipodia formation induced byWTor muta
was arbitrarily set to 1. Data are presented as the mean5 SEM of at
Statistical analysis in (B), (C), and (D) were made by one-way ANOVA
different from WT (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
(E) Micrographs of N1E-115 cells transfected with the indicated GFP-
the actin (red) and nuclei (blue), respectively. Representative images
mellipodia. Scale bar: 20 mm.
350 The American Journal of Human Genetics 106, 338–355, Marchnonsense mutations generate truncated products of
different size or haploinsufficiency after nonsense-medi-
ated decay of the aberrant transcripts. It is likely that all
these nonsense mutations will have different functional
consequences if they are expressed. For example, the
p.Gln1489Argfs*12 variant potentially generates a trun-
cated and, thus, a non-functional GEFD1. Interestingly,
the individuals harboring this mutation present with a
phenotype similar to that of the patients harboring
missense mutations in the GEFD1, suggesting that in this
case, the effect of the truncating variant is comparable to
the effect of the missense variants in the GEFD1. In
contrast, the two truncations p.Leu2031Phefs*9 and
p.Phe2473Serfs*54 supposedly produce large proteins
with a functional GEFD1, and we show that TRIO-induced
RAC1 activation is not affected by these variants. If these
truncated variants are expressed, their functional conse-
quences will probably be different from the missense mu-
tations in the GEFD1. Finally, we speculate that the
Gln768* variant is probably subject to nonsense-mediated
decay, thus generating haploinsufficiency. CharacterizingAK1 expression. PAK1 phosphorylation is used as a readout for the
ean5 SEM of at least five independent experiments.
t TRIO. Neurite outgrowth is monitored on the basis of the number
a. Data are presented as n-fold change over WT TRIO, which was
t five independent experiments.
nt TRIO. Data are presented as n-fold change overWT TRIO, which
least five independent experiments.
followed by Dunnett’s test. Asterisks indicate datasets significantly
0.0001).
TRIO variants (green); rhodamine-phalloidin and Hoechst stained
for each variant type are presented. White arrowheads point to la-
5, 2020
the contribution of these variants to the individuals’ phe-
notypes will require further research.
Concerning the missense mutations, we show here that
these segregate into two domain-specific hotspots that are
associated with differing and distinct clinical phenotypes.
We therefore propose that TRIO-associated pathologies
cover different neurological disorders depending on the
mutation location.
Missense mutations that cluster in the GEFD1 of TRIO
and affect the activation of RAC1 by TRIO have previously
been described.17–19 Here we describe a second mutational
cluster that targets three adjacent residues in the spectrin
repeat 7 of TRIO. Compared to the individuals harboring
mutations in GEFD1, individuals with missense mutations
within the spectrin cluster have more severe intellectual
disability, opposing macrocephaly, and statistically signifi-
cant clustering of facial dysmorphism. It is notable that
mutations within the same gene give rise to these strik-
ingly opposite effects on head size, ranging from a median
OFC of – 3.8 SD in the GEFD1-mutated individuals toþ 2.7
SD in the spectrin-mutated individuals. Interestingly, this
important difference in the magnitude of head size has
also been described for individuals harboring distinct mu-
tations in RAC1 (MIM: 602048), the main downstream
target of TRIO.49
To better understand how mutations in TRIO could
cause such different clinical spectra, we investigated the
consequences of these mutations on TRIO activity. The res-
idues mutated in the GEFD1, including the newly identi-
fied residues Glu 1299 and His 1469, lie in the a1, a5,
and a6 helices and are predicted to be in contact with
the Rho GTPases and to thereby catalyze the GDP-to-GTP
exchange.43 Indeed, all the mutants except Pro1461Leu
impair RAC1 binding and, consequently, TRIO-mediated
RAC1 activation, as measured by PAK1 phosphorylation.
In addition, these mutants are impaired in TRIO-mediated
neurite outgrowth and lamellipodia formation, which also
reflect RAC1 activation.50 One notable exception is the
Pro1461Leu variant, which does not lead to a reduction
in RAC1 activation. In contrast, this variant binds
RAC1 to a similar extent as WT TRIO and leads to a
modest increase in RAC1 activation, as measured by
TRIO-induced lamellipodia formation. Interestingly, the
two unrelated individuals (individuals 15 and 16) bearing
the Pro1461Leu variant are the only two persons who do
not present withmicrocephaly in the GEFD1 cohort. These
observations support a correlation between the level of
RAC1 activation by TRIO variants and head size. How
this variant contributes to the individuals’ phenotype
will need further investigation.
Interestingly, all the variants we identified in the TRIO
spectrin repeat (Thr1075Ile, Arg1078Trp/Gly/Gln, and
Asn1080Ile) have a strong TRIO-activating effect, inducing
hyperactivation of RAC1. This was measured both by PAK1
phosphorylation and by the formation of actin-rich lamel-
lipodia in N1E-115 cells. Because TRIO-mediated neurite
outgrowth is dependent on RAC1 activation, it is not sur-The Ameriprising that this process is consistently enhanced by these
variants. Contrary to the GEFD1, the spectrin repeats of
TRIO are not implicated in the direct activation of RAC1,
suggesting that this observed enhanced activity is due to
an indirect mechanism. Interestingly, the double TRIO
Arg1078Trp/GEFD1-defective mutant is unable to activate
RAC1, showing that the hyperactivation of RAC1 by TRIO
Arg1078Trp is strictly dependent on the activity of GEFD1
(M.B. and D.L., unpublished data). Based on these data, we
propose that mutations in the spectrin cluster perturb
mutual arrangement of a helices in the seventh spectrin
repeat and affect overall TRIO fold and/or signaling, lead-
ing to hyperactivation of RAC1 by TRIO. The spectrin
domains within TRIO are known to bind different TRIO
regulators, such as Kidins220, DISC1, and NAV1.34,51,52 It
has also been proposed that spectrin repeats inhibit
TRIO-mediated RAC1 activation by intramolecular bind-
ing to the GEFD1 and thus prevent TRIO-RAC1 binding
and that the binding of DISC1 releases this intramolecular
inhibition.52 Whether the mutations found in affected in-
dividuals perturb this intramolecular binding or the bind-
ing to different partners will be the subject of further
investigation.
This hypothesis is also supported by our molecular
modeling studies based on the crystal structure of the hu-
man b2 spectrin.We observed that the cluster of mutations
identified in affected individuals lies in the second a helix
of the spectrin repeat. The Arg 1078 residue faces another a
helix, whereas the Thr 1075 and Asn 1080 residues are
exposed on the external side of the helix. Interestingly, in-
dividuals harboring TRIO Arg 1078 variants display the
most severe phenotype. In addition, among the TRIO Arg
1078 variants, Arg1078Trp is the most frequent and gives
rise to the strongest phenotype. The tryptophan brings
an important steric constraint as a result of its large size,
suggesting that mutations of the Arg 1078 residue prob-
ably affect the structural organization of the three a helices
of spectrin repeat 7, leading to perturbed TRIO folding
and/or binding to its partners and ultimately altering
TRIO activity.
Combined, our data show that mutations in two
different hotspots negatively or positively affect RAC1 acti-
vation by TRIO and indicate that these mutations repre-
sent loss- or gain-of-function mutations that give rise to
distinct developmental defects. Our data show that the
different RAC1 activation levels dependent on the muta-
tion are well correlated to the head size of the affected in-
dividuals. In line with this, TRIO depletion in mice causes
neurodevelopmental deficits associated with a decrease in
brain size.13,14 This was also supported by our experiments
in Xenopus expressing different TRIO variants that resulted
in phenotypes concordant with those of affected humans.
This finding adds to the evidence that F0 X. tropicalis
embryos produced by gene editing can be used effectively
in the study of human gene variants. Indeed, mimicking a
GEFD1 variant in Xenopus produces microcephaly as
in humans, whereas making a variant with a truncatedcan Journal of Human Genetics 106, 338–355, March 5, 2020 351
GEFD2 has little effect in either humans or frogs. Unfortu-
nately, technical limitations currently prevent us from
introducing missense mutations in X. tropicalis, and there-
fore, we could not directly test whether a missense muta-
tion overactivating RAC1 in group 1 would induce macro-
cephaly in the frog. Nonetheless, our data provide strong
evidence that missense TRIO mutations inducing RAC1
overactivation are associated with macrocephaly. Indeed,
in our study we describe seven independent individuals
who have the same targeted residue (Arg1078Trp/Gly/
Gln) and all present with macrocephaly. This important
number of independent individuals with a similar pheno-
type reduces the potential contribution of other variants to
the phenotype and strongly suggests that hyperactivation
of RAC1 by TRIO is associated with macrocephaly.
Perturbation of head size often results from dysregula-
tion of early developmental pathways, such as prolifera-
tion and/or apoptosis or neural migration of the cortex,
in neural progenitor cells (NPCs). Interestingly, RAC1 defi-
ciency in the forebrain of mice leads to a smaller forebrain
resembling the microcephaly phenotype.53 It has been
proposed that this microcephaly results from a reduction
of NPCs as a result of an accelerated cell-cycle exit, com-
bined with increased apoptosis of nascent neurons and dis-
rupted differentiation of post-mitotic neurons.54 Of note,
we have previously shown that TRIO is important for cyto-
kinesis,7 suggesting that perturbation of TRIO activity
could affect the cell cycle of NPCs.
Given the large body of evidence implicating TRIO in
different aspects of brain development, we speculate that
TRIO mutations might affect other neuronal processes,
including axon guidance and the formation of synapses.
This hypothesis is reinforced by previous data showing
that conditional deletion of RAC1 and RAC3 in mouse neu-
rons leads tomigration, differentiation, andconnectivity de-
fects.55–57 Perturbation of synapses by TRIO depletion or by
missense mutations has already been described in vitro and
in vivo.10,16,18 TRIO is an important component of the ne-
trin-1-dependent pathway, which is important for axon
guidance, and TRIO depletion in mice results in defects in
the corpus callosum’s axonal projections, which are netrin-
1 dependent.58 Interestingly, we describe here numerous
structural brain anomalies in two affected individuals, one
of whomhas partial corpus callosum agenesis with an inter-
hemispheric cyst and the other of whom has loss of white
matter volume, asymmetric enlargement of the ventricles,
and a thin corpus callosum. These data suggest that TRIO-
affected individuals might also exhibit defects in the axonal
guidance process during early development.
Our data also highlight the importance of strict control
of the level of RAC1 activation for proper neuronal devel-
opment. In conjunction with this, distinct RAC1 variants
have been shown to have a positive or negative effect on
RAC1 function and to cause diverse phenotypes.49 Distinct
phenotypes that correlate to activating or inactivating mu-
tations at different locations in the gene have also been
described in PAK1 and PAK3 (MIM: 618158).59–61 Together,352 The American Journal of Human Genetics 106, 338–355, Marchour data reinforce the hypothesis that the TRIO/RAC1/PAK
axis is a major pathway for neuronal development that is
perturbed in neurodevelopmental diseases. Interestingly,
PAK1 inhibition has been used to reverse behavior defects
in mice.59,62 These observations suggest an avenue for
therapeutic intervention for TRIO disorders associated
with a hyperactivation of RAC1 via a pharmacological
strategy targeting PAK1 activation.
In conclusion, we have identified two clusters of TRIO
mutations associated with distinct clinical and neurodeve-
lopmental phenotypes attributable to differing levels of
RAC1 activation. We suggest a genotype-phenotype corre-
lation based on the location of the mutation; this correla-
tion will serve as a useful adjunct for clinical evaluation
and the interpretation of variant pathogenicity. In addi-
tion, and by using the previously reported hybrid model
for quantitative facial phenotyping, we see that the spec-
trin-mutated group has a distinctive facial gestalt assess-
able through the algorithms.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2020.01.018.Acknowledgments
We are grateful to all the patients and their families for their partic-
ipation in this study.We thank all members of the Debant team for
helpful discussions. We acknowledge the imaging facility Mont-
pellier Ressources Imagerie (MRI), a member of the national
France-BioImaging infrastructure supported by the French Na-
tional Research Agency (ANR-10-INBS-04, ‘‘Investments for the
future’’). We thank A. Guille for help with statistical analysis.
This work was supported by grants from the Fondation pour la Re-
cherche Me´dicale (Equipes FRM 2016, DEQ20160334942) to A.D.
A PhD fellowship from the Ministe`re de l’Enseignement Supe´rieur
et de la Recherche supported M.B. The European Xenopus
Resource Centre (EXRC) is funded by the Wellcome Trust
(212942/Z/18/Z) and the Biotechnology and Biological Sciences
Research Council (BB/R014841/1). The Baralle lab is supported
by a National Institute for Health Research research professorship
to D.B. (RP-2016-07-011). S.G.-H. is funded by a research fellow-
ship from the Health Education England Genomics Education
Programme. The DDD study presents independent research
commissioned by the Health Innovation Challenge Fund [grant
HICF-1009-003]. This research was made possible through access
to data and findings generated by the 100,000 Genomes Project,
which is managed by Genomics England Limited (a wholly owned
company of the Department of Health and Social Care). The
100,000 Genomes Project is funded by the National Institute for
Health Research and NHS England. The Wellcome Trust, Cancer
Research UK, and the Medical Research Council have also funded
research infrastructure. The 100,000 Genomes Project uses data
provided by patients and collected by the National Health Service
as part of their care and support.Declaration of Interests
The authors declare no competing interests.5, 2020
Received: October 11, 2019
Accepted: January 27, 2020
Published: February 27, 2020Web Resources
CRISPRscan, https://www.crisprscan.org/
DDD UK, https://www.ddduk.org/access.html
DECIPHER, https://decipher.sanger.ac.uk/
The National Genomics Research and Healthcare Knowledgebase
v5, https://www.genomicsengland.co.uk/the-national-genomics-
research-and-healthcare-knowledgebase/
Online Mendelian Inheritance in Man (OMIM), https://www.
omim.org/
Primer3, http://primer3.ut.ee
Xenbase, http://www.xenbase.org/entry; V9.1 of the genomeReferences
1. Govek, E.E., Newey, S.E., and Van Aelst, L. (2005). The role of
the Rho GTPases in neuronal development. Genes Dev. 19,
1–49.
2. Tolias, K.F., Duman, J.G., and Um, K. (2011). Control of syn-
apse development and plasticity by Rho GTPase regulatory
proteins. Prog. Neurobiol. 94, 133–148.
3. Debant, A., Serra-Page`s, C., Seipel, K., O’Brien, S., Tang,
M., Park, S.H., and Streuli, M. (1996). The multidomain
protein Trio binds the LAR transmembrane tyrosine phos-
phatase, contains a protein kinase domain, and has sepa-
rate rac-specific and rho-specific guanine nucleotide ex-
change factor domains. Proc. Natl. Acad. Sci. USA 93,
5466–5471.
4. Blangy, A., Vignal, E., Schmidt, S., Debant, A., Gauthier-Rou-
vie`re, C., and Fort, P. (2000). TrioGEF1 controls Rac- and
Cdc42-dependent cell structures through the direct activation
of rhoG. J. Cell Sci. 113, 729–739.
5. Bellanger, J.M., Lazaro, J.B., Diriong, S., Fernandez, A., Lamb,
N., and Debant, A. (1998). The two guanine nucleotide ex-
change factor domains of Trio link the Rac1 and the RhoA
pathways in vivo. Oncogene 16, 147–152.
6. Schmidt, S., andDebant, A. (2014). Function and regulation of
the Rho guanine nucleotide exchange factor Trio. Small
GTPases 5, e29769.
7. Cannet, A., Schmidt, S., Delaval, B., and Debant, A. (2014).
Identification of a mitotic Rac-GEF, Trio, that counteracts
MgcRacGAP function during cytokinesis. Mol. Biol. Cell 25,
4063–4071.
8. Iyer, S.C., Wang, D., Iyer, E.P., Trunnell, S.A., Meduri, R.,
Shinwari, R., Sulkowski, M.J., and Cox, D.N. (2012). The
RhoGEF trio functions in sculpting class specific dendrite
morphogenesis in Drosophila sensory neurons. PLoS ONE
7, e33634.
9. Ba, W., van der Raadt, J., and Nadif Kasri, N. (2013). Rho
GTPase signaling at the synapse: implications for intellectual
disability. Exp. Cell Res. 319, 2368–2374.
10. Herring, B.E., and Nicoll, R.A. (2016). Kalirin and Trio proteins
serve critical roles in excitatory synaptic transmission and LTP.
Proc. Natl. Acad. Sci. USA 113, 2264–2269.
11. O’Brien, S.P., Seipel, K., Medley, Q.G., Bronson, R., Segal, R.,
and Streuli, M. (2000). Skeletal muscle deformity and
neuronal disorder in Trio exchange factor-deficient mouse
embryos. Proc. Natl. Acad. Sci. USA 97, 12074–12078.The Ameri12. Peng, Y.J., He, W.Q., Tang, J., Tao, T., Chen, C., Gao, Y.Q.,
Zhang, W.C., He, X.Y., Dai, Y.Y., Zhu, N.C., et al. (2010). Trio
is a key guanine nucleotide exchange factor coordinating
regulation of the migration and morphogenesis of granule
cells in the developing cerebellum. J. Biol. Chem. 285,
24834–24844.
13. Zong,W., Liu, S., Wang, X., Zhang, J., Zhang, T., Liu, Z., Wang,
D., Zhang, A., Zhu,M., andGao, J. (2015). Trio gene is required
for mouse learning ability. Brain Res. 1608, 82–90.
14. Katrancha, S.M., Shaw, J.E., Zhao, A.Y., Myers, S.A., Cocco,
A.R., Jeng, A.T., Zhu, M., Pittenger, C., Greer, C.A., Carr, S.A.,
et al. (2019). Trio Haploinsufficiency Causes Neurodevelop-
mental Disease-Associated Deficits. Cell Rep. 26, 2805–
2817.e9.
15. Tao, T., Sun, J., Peng, Y., Wang, P., Chen, X., Zhao, W., Li, Y.,
Wei, L., Wang, W., Zheng, Y., et al. (2019). Distinct functions
of Trio GEF domains in axon outgrowth of cerebellar granule
neurons. J. Genet. Genomics 46, 87–96.
16. Ba, W., Yan, Y., Reijnders, M.R., Schuurs-Hoeijmakers, J.H.,
Feenstra, I., Bongers, E.M., Bosch, D.G., De Leeuw, N., Pfundt,
R., Gilissen, C., et al. (2016). TRIO loss of function is associ-
ated with mild intellectual disability and affects dendritic
branching and synapse function. Hum. Mol. Genet. 25,
892–902.
17. Pengelly, R.J., Greville-Heygate, S., Schmidt, S., Seaby, E.G., Ja-
balameli, M.R., Mehta, S.G., Parker, M.J., Goudie, D., Fagotto-
Kaufmann, C., Mercer, C., et al.; DDD Study (2016). Mutations
specific to the Rac-GEF domain of TRIO cause intellectual
disability and microcephaly. J. Med. Genet. 53, 735–742.
18. Sadybekov, A., Tian, C., Arnesano, C., Katritch, V., and Her-
ring, B.E. (2017). An autism spectrum disorder-related de
novo mutation hotspot discovered in the GEF1 domain of
Trio. Nat. Commun. 8, 601.
19. Katrancha, S.M., Wu, Y., Zhu, M., Eipper, B.A., Koleske, A.J.,
and Mains, R.E. (2017). Neurodevelopmental disease-associ-
ated de novo mutations and rare sequence variants affect
TRIO GDP/GTP exchange factor activity. Hum. Mol. Genet.
26, 4728–4740.
20. Petrovski, S., Wang, Q., Heinzen, E.L., Allen, A.S., and Gold-
stein, D.B. (2013). Genic intolerance to functional variation
and the interpretation of personal genomes. PLoS Genet. 9,
e1003709.
21. Deciphering Developmental Disorders Study (2015). Large-
scale discovery of novel genetic causes of developmental dis-
orders. Nature 519, 223–228.
22. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R., Thor-
mann, A., Flicek, P., and Cunningham, F. (2016). The Ensembl
Variant Effect Predictor. Genome Biol. 17, 122.
23. Desmet, F.-O., Hamroun, D., Lalande, M., Collod-Be´roud, G.,
Claustres, M., and Be´roud, C. (2009). Human Splicing Finder:
an online bioinformatics tool to predict splicing signals. Nu-
cleic Acids Res. 37, e67.
24. Yeo, G., and Burge, C.B. (2004). Maximum entropy modeling
of short sequence motifs with applications to RNA splicing
signals. J. Comput. Biol. 11, 377–394.
25. Reese, M.G., Eeckman, F.H., Kulp, D., and Haussler, D. (1997).
Improved splice site detection in Genie. J. Comput. Biol. 4,
311–323.
26. van der Donk, R., Jansen, S., Schuurs-Hoeijmakers, J.H.M.,
Koolen, D.A., Goltstein, L.C.M.J., Hoischen, A., Brunner,
H.G., Kemmeren, P., Nella˚ker, C., Vissers, L.E.L.M., et al.
(2019). Next-generation phenotyping using computer visioncan Journal of Human Genetics 106, 338–355, March 5, 2020 353
algorithms in rare genomic neurodevelopmental disorders.
Genet. Med. 21, 1719–1725.
27. Diets, I.J., van der Donk, R., Baltrunaite, K., Waanders, E., Re-
ijnders, M.R.F., Dingemans, A.J.M., Pfundt, R., Vulto-van
Silfhout, A.T., Wiel, L., Gilissen, C., et al. (2019). De Novo
and Inherited Pathogenic Variants in KDM3B Cause Intellec-
tual Disability, Short Stature, and Facial Dysmorphism. Am.
J. Hum. Genet. 104, 758–766.
28. Amos, B., Ludwiczuk, B., and Satyanarayanan, M. (2016).
OpenFace: A general-purpose face recognition library with
mobile applications. (Carnegie Mellon School of Computer
Science), CMU–CD–16–188.
29. Ferry, Q., Steinberg, J., Webber, C., FitzPatrick, D.R., Ponting,
C.P., Zisserman, A., and Nella˚ker, C. (2014). Diagnostically
relevant facial gestalt information from ordinary photos. eLife
3, e02020.
30. Davis, L., Abdi, K., Machius, M., Brautigam, C., Tomchick,
D.R., Bennett, V., and Michaely, P. (2009). Localization and
structure of the ankyrin-binding site on beta2-spectrin.
J. Biol. Chem. 284, 6982–6987.
31. Bucher, P., Karplus, K., Moeri, N., and Hofmann, K. (1996). A
flexible motif search technique based on generalized profiles.
Comput. Chem. 20, 3–23.
32. Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello,
G., Gumienny, R., Heer, F.T., de Beer, T.A.P., Rempfer, C., Bor-
doli, L., et al. (2018). SWISS-MODEL: homology modelling of
protein structures and complexes. Nucleic Acids Res. 46 (W1),
W296–W303.
33. DeLano, W.L. (2002). The PyMOL Molecular Graphics System
(San Carlos: Delano Scientific).
34. van Haren, J., Boudeau, J., Schmidt, S., Basu, S., Liu, Z., Lam-
mers, D., Demmers, J., Benhari, J., Grosveld, F., Debant, A.,
and Galjart, N. (2014). Dynamic microtubules catalyze forma-
tion of navigator-TRIO complexes to regulate neurite exten-
sion. Curr. Biol. 24, 1778–1785.
35. Estrach, S., Schmidt, S., Diriong, S., Penna, A., Blangy, A., Fort,
P., and Debant, A. (2002). The Human Rho-GEF trio and its
target GTPase RhoG are involved in the NGF pathway, leading
to neurite outgrowth. Curr. Biol. 12, 307–312.
36. DeGeer, J., Boudeau, J., Schmidt, S., Bedford, F., Lamarche-
Vane, N., and Debant, A. (2013). Tyrosine phosphorylation
of the Rho guanine nucleotide exchange factor Trio regulates
netrin-1/DCC-mediated cortical axon outgrowth. Mol. Cell.
Biol. 33, 739–751.
37. Sargent, M.G., and Mohun, T.J. (2005). Cryopreservation of
sperm of Xenopus laevis and Xenopus tropicalis. Genesis 41,
41–46.
38. Mansour, N., Lahnsteiner, F., and Patzner, R.A. (2009). Optimi-
zation of the cryopreservation of African clawed frog (Xeno-
pus laevis) sperm. Theriogenology 72, 1221–1228.
39. Pearl, E., Morrow, S., Noble, A., Lerebours, A., Horb, M., and
Guille, M. (2017). An optimized method for cryogenic
storage of Xenopus sperm to maximise the effectiveness of
research using genetically altered frogs. Theriogenology 92,
149–155.
40. Nakayama, T., Blitz, I.L., Fish, M.B., Odeleye, A.O., Manohar,
S., Cho, K.W., and Grainger, R.M. (2014). Cas9-based genome
editing in Xenopus tropicalis. Methods Enzymol. 546,
355–375.
41. Guille, M. (1999). Molecular Methods in Developmental
Biology: Xenopus and Zebrafish, Volume 27 (Springer Science
& Business Media).354 The American Journal of Human Genetics 106, 338–355, March42. Vouillot, L., The´lie, A., and Pollet, N. (2015). Comparison of
T7E1 and surveyor mismatch cleavage assays to detect muta-
tions triggered by engineered nucleases. G3 (Bethesda) 5,
407–415.
43. Chhatriwala, M.K., Betts, L., Worthylake, D.K., and Sondek, J.
(2007). The DH and PH domains of Trio coordinately engage
Rho GTPases for their efficient activation. J. Mol. Biol. 368,
1307–1320.
44. Ladwein, M., and Rottner, K. (2008). On the Rho’d: the regu-
lation of membrane protrusions by Rho-GTPases. FEBS Lett.
582, 2066–2074.
45. Deniz, E., Mis, E.K., Lane, M., and Khokha, M.K. (2018).
CRISPR/Cas9 F0 Screening of Congenital Heart Disease
Genes in Xenopus tropicalis. Methods Mol. Biol. 1865,
163–174.
46. Naert, T., Colpaert, R., Van Nieuwenhuysen, T., Dimitrako-
poulou, D., Leoen, J., Haustraete, J., Boel, A., Steyaert, W.,
Lepez, T., Deforce, D., et al. (2016). CRISPR/Cas9 mediated
knockout of rb1 and rbl1 leads to rapid and penetrant retino-
blastoma development in Xenopus tropicalis. Sci. Rep. 6,
35264.
47. Naert, T., and Vleminckx, K. (2018). CRISPR/Cas9 disease
models in zebrafish and Xenopus: The genetic renaissance of
fish and frogs. Drug Discov. Today. Technol. 28, 41–52.
48. Sega, A.G., Mis, E.K., Lindstrom, K., Mercimek-Andrews, S., Ji,
W., Cho, M.T., Juusola, J., Konstantino, M., Jeffries, L., Kho-
kha, M.K., and Lakhani, S.A. (2019). De novo pathogenic
variants in neuronal differentiation factor 2 (NEUROD2)
cause a form of early infantile epileptic encephalopathy.
J. Med. Genet. 56, 113–122.
49. Reijnders, M.R.F., Ansor, N.M., Kousi, M., Yue, W.W., Tan, P.L.,
Clarkson, K., Clayton-Smith, J., Corning, K., Jones, J.R., Lam,
W.W.K., et al.; Deciphering Developmental Disorders Study
(2017). RAC1 Missense Mutations in Developmental Disor-
ders with Diverse Phenotypes. Am. J. Hum. Genet. 101,
466–477.
50. Meyer, G., and Feldman, E.L. (2002). Signaling mechanisms
that regulate actin-basedmotility processes in the nervous sys-
tem. J. Neurochem. 83, 490–503.
51. Neubrand, V.E., Thomas, C., Schmidt, S., Debant, A., and
Schiavo, G. (2010). Kidins220/ARMS regulates Rac1-depen-
dent neurite outgrowth by direct interaction with the RhoGEF
Trio. J. Cell Sci. 123, 2111–2123.
52. Chen, S.Y., Huang, P.H., and Cheng, H.J. (2011). Disrupted-in-
Schizophrenia 1-mediated axon guidance involves TRIO-RAC-
PAK small GTPase pathway signaling. Proc. Natl. Acad. Sci.
USA 108, 5861–5866.
53. Chen, L., Melendez, J., Campbell, K., Kuan, C.-Y., and Zheng,
Y. (2009). Rac1 deficiency in the forebrain results in neural
progenitor reduction and microcephaly. Dev. Biol. 325,
162–170.
54. Leone, D.P., Srinivasan, K., Brakebusch, C., and McConnell,
S.K. (2010). The rho GTPase Rac1 is required for proliferation
and survival of progenitors in the developing forebrain. Dev.
Neurobiol. 70, 659–678.
55. Vaghi, V., Pennucci, R., Talpo, F., Corbetta, S., Montinaro, V.,
Barone, C., Croci, L., Spaiardi, P., Consalez, G.G., Biella, G.,
and de Curtis, I. (2014). Rac1 and rac3 GTPases control syner-
gistically the development of cortical and hippocampal
GABAergic interneurons. Cereb. Cortex 24, 1247–1258.
56. Corbetta, S., Gualdoni, S., Ciceri, G., Monari, M., Zuccaro, E.,
Tybulewicz, V.L., and de Curtis, I. (2009). Essential role of Rac15, 2020
and Rac3 GTPases in neuronal development. FASEB J. 23,
1347–1357.
57. Pennucci, R., Tavano, S., Tonoli, D., Gualdoni, S., and de Cur-
tis, I. (2011). Rac1 and Rac3GTPases regulate the development
of hilar mossy cells by affecting the migration of their precur-
sors to the hilus. PLoS ONE 6, e24819.
58. Brianc¸on-Marjollet, A., Ghogha, A., Nawabi, H., Triki, I., Au-
ziol, C., Fromont, S., Piche´, C., Enslen, H., Chebli, K., Cloutier,
J.F., et al. (2008). Trio mediates netrin-1-induced Rac1 activa-
tion in axon outgrowth and guidance. Mol. Cell. Biol. 28,
2314–2323.
59. Harms, F.L., Kloth, K., Bley, A., Denecke, J., Santer, R., Lessel,
D., Hempel, M., and Kutsche, K. (2018). Activating Mutations
in PAK1, Encoding p21-Activated Kinase 1, Cause a Neurode-
velopmental Disorder. Am. J. Hum. Genet. 103, 579–591.The Ameri60. Allen, K.M., Gleeson, J.G., Bagrodia, S., Partington, M.W.,
MacMillan, J.C., Cerione, R.A., Mulley, J.C., and Walsh, C.A.
(1998). PAK3 mutation in nonsyndromic X-linked mental
retardation. Nat. Genet. 20, 25–30.
61. Horn, S., Au, M., Basel-Salmon, L., Bayrak-Toydemir, P., Cha-
pin, A., Cohen, L., Elting,M.W., Graham, J.M., Gonzaga-Jaure-
gui, C., Konen, O., et al. (2019). De novo variants in PAK1 lead
to intellectual disabilitywithmacrocephaly and seizures. Brain
142, 3351–3359. https://doi.org/10.1093/brain/awz264.
62. Dolan, B.M., Duron, S.G., Campbell, D.A., Vollrath, B., Shan-
karanarayana Rao, B.S., Ko, H.Y., Lin, G.G., Govindarajan, A.,
Choi, S.Y., and Tonegawa, S. (2013). Rescue of fragile X syn-
drome phenotypes in Fmr1 KO mice by the small-molecule
PAK inhibitor FRAX486. Proc. Natl. Acad. Sci. USA 110,
5671–5676.can Journal of Human Genetics 106, 338–355, March 5, 2020 355
